U.S. Markets closed
  • S&P Futures

    3,900.25
    -16.00 (-0.41%)
     
  • Dow Futures

    31,360.00
    -127.00 (-0.40%)
     
  • Nasdaq Futures

    12,095.25
    -45.25 (-0.37%)
     
  • Russell 2000 Futures

    1,753.90
    -7.80 (-0.44%)
     
  • Crude Oil

    105.91
    -1.71 (-1.59%)
     
  • Gold

    1,830.50
    +0.20 (+0.01%)
     
  • Silver

    21.08
    -0.04 (-0.19%)
     
  • EUR/USD

    1.0561
    +0.0002 (+0.0211%)
     
  • 10-Yr Bond

    3.1250
    +0.0570 (+1.86%)
     
  • Vix

    27.23
    -1.82 (-6.27%)
     
  • GBP/USD

    1.2274
    +0.0004 (+0.0344%)
     
  • USD/JPY

    134.6250
    -0.5450 (-0.4032%)
     
  • BTC-USD

    21,061.13
    -413.18 (-1.92%)
     
  • CMC Crypto 200

    458.13
    +4.24 (+0.93%)
     
  • FTSE 100

    7,208.81
    +188.36 (+2.68%)
     
  • Nikkei 225

    26,728.78
    +236.81 (+0.89%)
     

Here's Why We're Watching Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Situation

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a fortune. But while history lauds those rare successes, those that fail are often forgotten; who remembers Pets.com?

So should Nuvectis Pharma (NASDAQ:NVCT) shareholders be worried about its cash burn? For the purposes of this article, cash burn is the annual rate at which an unprofitable company spends cash to fund its growth; its negative free cash flow. We'll start by comparing its cash burn with its cash reserves in order to calculate its cash runway.

See our latest analysis for Nuvectis Pharma

When Might Nuvectis Pharma Run Out Of Money?

A company's cash runway is calculated by dividing its cash hoard by its cash burn. As at March 2022, Nuvectis Pharma had cash of US$17m and no debt. Looking at the last year, the company burnt through US$13m. So it had a cash runway of approximately 16 months from March 2022. That's not too bad, but it's fair to say the end of the cash runway is in sight, unless cash burn reduces drastically. Depicted below, you can see how its cash holdings have changed over time.

debt-equity-history-analysis
debt-equity-history-analysis

How Is Nuvectis Pharma's Cash Burn Changing Over Time?

Nuvectis Pharma didn't record any revenue over the last year, indicating that it's an early stage company still developing its business. So while we can't look to sales to understand growth, we can look at how the cash burn is changing to understand how expenditure is trending over time. Its cash burn positively exploded in the last year, up 437%. Given that sharp increase in spending, the company's cash runway will shrink rapidly as it depletes its cash reserves. Clearly, however, the crucial factor is whether the company will grow its business going forward. For that reason, it makes a lot of sense to take a look at our analyst forecasts for the company.

How Hard Would It Be For Nuvectis Pharma To Raise More Cash For Growth?

Given its cash burn trajectory, Nuvectis Pharma shareholders may wish to consider how easily it could raise more cash, despite its solid cash runway. Companies can raise capital through either debt or equity. Many companies end up issuing new shares to fund future growth. By comparing a company's annual cash burn to its total market capitalisation, we can estimate roughly how many shares it would have to issue in order to run the company for another year (at the same burn rate).

Nuvectis Pharma has a market capitalisation of US$144m and burnt through US$13m last year, which is 8.7% of the company's market value. That's a low proportion, so we figure the company would be able to raise more cash to fund growth, with a little dilution, or even to simply borrow some money.

How Risky Is Nuvectis Pharma's Cash Burn Situation?

On this analysis of Nuvectis Pharma's cash burn, we think its cash burn relative to its market cap was reassuring, while its increasing cash burn has us a bit worried. We don't think its cash burn is particularly problematic, but after considering the range of factors in this article, we do think shareholders should be monitoring how it changes over time. On another note, Nuvectis Pharma has 5 warning signs (and 2 which don't sit too well with us) we think you should know about.

If you would prefer to check out another company with better fundamentals, then do not miss this free list of interesting companies, that have HIGH return on equity and low debt or this list of stocks which are all forecast to grow.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.